Skip to main content
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 10/2008

01.10.2008 | Original Article

Concordance between results of somatostatin receptor scintigraphy with 111In-DOTA-DPhe1-Tyr3-octreotide and chromogranin A assay in patients with neuroendocrine tumours

verfasst von: Margarida Rodrigues, Michael Gabriel, Dirk Heute, Daniel Putzer, Andrea Griesmacher, Irene Virgolini

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 10/2008

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Somatostatin receptor scintigraphy (SRS) and chromogranin A (CgA) assay have successfully been implemented in the clinical work-up and management of neuroendocrine tumour (NET) patients. However, there is still a lack of studies comparing results in these patients. Our aim was to compare directly in NET patients SRS and CgA assay results with special regard to tumour features such as grade of malignancy, primary origin, disease extent and function.

Methods

One hundred twenty consecutive patients with histological confirmed NETs were investigated with 111In-DOTA-DPhe1-Tyr3-octreotide (111In-DOTA-TOC) SRS and CgA immunoradiometric assay. Tumours were classified by cell characteristics [well-differentiated NETs, well-differentiated neuroendocrine carcinomas, poorly differentiated neuroendocrine carcinomas (PDNECs)], primary origin (foregut, midgut, hindgut, undetermined), disease extent (limited disease, metastases, primary tumour and metastases) and functionality (secretory, nonsecretory).

Results

SRS was positive in 107 (89%) patients; CgA levels were increased in 95 (79%) patients. Overall, concordance between SRS and CgA results was found in 84 patients. Positive SRS but normal CgA level were found in 24 patients, with higher prevalence (p < 0.05) in patients with nonsecretory tumours. Conversely, negative SRS but CgA level increased were seen in 12 patients, with higher proportion (p < 0.05) in patients with PDNECs and tumours of hindgut origin.

Conclusions

Overall, 111In-DOTA-TOC SRS proved to be more sensitive than CgA in NETs patients. Tumour differentiation, disease extent and presence of liver metastases impact both SRS and CgA results, whereas nonsecretory activity is a negative predictor of only CgA increase. PDNECs and hindgut origin of tumours predispose to discrepancies with negative SRS but increased CgA levels.
Literatur
1.
Zurück zum Zitat Plöckinger U, Rindi G, Arnold R, Eriksson B, Krenning EP, de Herder WW, et al. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology 2004;80:394–424.PubMedCrossRef Plöckinger U, Rindi G, Arnold R, Eriksson B, Krenning EP, de Herder WW, et al. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology 2004;80:394–424.PubMedCrossRef
2.
Zurück zum Zitat Solcia E, Klöppel G, Sobin LH, Capella C, DeLellis RA, Heitz PU, et al. Histological typing of endocrine tumours: WHO international histological classification of tumours. 2nd ed. Berlin: Springer; 2000. Solcia E, Klöppel G, Sobin LH, Capella C, DeLellis RA, Heitz PU, et al. Histological typing of endocrine tumours: WHO international histological classification of tumours. 2nd ed. Berlin: Springer; 2000.
3.
Zurück zum Zitat Papadogias D, Makras P, Griniatsos I, Kaltsas G, Grossman A. Advances in the detection and management of neuroendocrine (carcinoid and pancreatic islet cell) tumours. Curr Opin Endocrinol Diabetes 2006;13:356–61.CrossRef Papadogias D, Makras P, Griniatsos I, Kaltsas G, Grossman A. Advances in the detection and management of neuroendocrine (carcinoid and pancreatic islet cell) tumours. Curr Opin Endocrinol Diabetes 2006;13:356–61.CrossRef
4.
Zurück zum Zitat Peracchi M, Conte D, Gebbia C, Penati C, Pizzinelli S, Arosio M, et al. Plasma chromogranin A in patients with sporadic gastro-entero-pancreatic neuroendocrine tumors or multiple endocrine neoplasia type 1. Eur J Endocrinology 2003;148:39–43.CrossRef Peracchi M, Conte D, Gebbia C, Penati C, Pizzinelli S, Arosio M, et al. Plasma chromogranin A in patients with sporadic gastro-entero-pancreatic neuroendocrine tumors or multiple endocrine neoplasia type 1. Eur J Endocrinology 2003;148:39–43.CrossRef
5.
Zurück zum Zitat Ramage JK, Davies AHG, Ardill J, Bax N, Caplin M, Grossman A, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut 2005;54:1–16.CrossRef Ramage JK, Davies AHG, Ardill J, Bax N, Caplin M, Grossman A, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut 2005;54:1–16.CrossRef
6.
Zurück zum Zitat Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, et al. Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20:716–31.PubMedCrossRef Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, et al. Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20:716–31.PubMedCrossRef
7.
Zurück zum Zitat Rufini V, Calcagni M, Baum R. Imaging of neuroendocrine tumors. Semin Nucl Med 2006;36:228–47.PubMedCrossRef Rufini V, Calcagni M, Baum R. Imaging of neuroendocrine tumors. Semin Nucl Med 2006;36:228–47.PubMedCrossRef
8.
Zurück zum Zitat Deftos LJ. Chromogranin A: its role in endocrine function and as an endocrine and neuroendocrine tumor marker. Endocrine Reviews 1991;12:181–7.PubMed Deftos LJ. Chromogranin A: its role in endocrine function and as an endocrine and neuroendocrine tumor marker. Endocrine Reviews 1991;12:181–7.PubMed
9.
Zurück zum Zitat Ricke J, Klose KJ, Mignon M, Oberg K, Wiedenmann B. Standardisation of imaging in neuroendocrine tumours: results of a European delphi process. Eur J Radiol 2001;37:8–17.PubMedCrossRef Ricke J, Klose KJ, Mignon M, Oberg K, Wiedenmann B. Standardisation of imaging in neuroendocrine tumours: results of a European delphi process. Eur J Radiol 2001;37:8–17.PubMedCrossRef
10.
Zurück zum Zitat Janson ET, Stridsberg M, Gobl A, Westlin JE, Oberg K. Determination of somatostatin receptor subtype 2 in carcinoid tumors by immunohistochemical investigation with somatostatin receptor subtype 2 antibodies. Cancer Res 1998;58:2375–8.PubMed Janson ET, Stridsberg M, Gobl A, Westlin JE, Oberg K. Determination of somatostatin receptor subtype 2 in carcinoid tumors by immunohistochemical investigation with somatostatin receptor subtype 2 antibodies. Cancer Res 1998;58:2375–8.PubMed
11.
Zurück zum Zitat Papotti M, Croce S, Macri L, Funaro A, Pecchioni C, Schindler M, et al. Correlative immunohistochemical and reverse transcriptase polymerase chain reaction analysis of somatostatin receptor type 2 in neuroendocrine tumors of the lung. Diagn Mol Pathol 2000;9:47–57.PubMedCrossRef Papotti M, Croce S, Macri L, Funaro A, Pecchioni C, Schindler M, et al. Correlative immunohistochemical and reverse transcriptase polymerase chain reaction analysis of somatostatin receptor type 2 in neuroendocrine tumors of the lung. Diagn Mol Pathol 2000;9:47–57.PubMedCrossRef
12.
Zurück zum Zitat Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 2001;28:836–46.PubMedCrossRef Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 2001;28:836–46.PubMedCrossRef
13.
Zurück zum Zitat Reubi JC, Schaer JC, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000;27:273–82.PubMedCrossRef Reubi JC, Schaer JC, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000;27:273–82.PubMedCrossRef
14.
Zurück zum Zitat Kwekkeboom D, Krenning EP, de Jong M. Peptide receptor imaging and therapy. J Nucl Med 2000;41:1704–13.PubMed Kwekkeboom D, Krenning EP, de Jong M. Peptide receptor imaging and therapy. J Nucl Med 2000;41:1704–13.PubMed
15.
Zurück zum Zitat Virgolini I, Patri P, Novotny C, Traub T, Leimer M, Füger B, et al. Comparative somatostatin receptor scintigraphy using In-111-DOTA-lanreotide and In-111-DOTA-Tyr3-octreotide versus F-18-FDG-PET for evaluation of somatostatin receptor-mediated radionuclide therapy. Ann Oncol 2001;12 suppl. 2:41–5.CrossRef Virgolini I, Patri P, Novotny C, Traub T, Leimer M, Füger B, et al. Comparative somatostatin receptor scintigraphy using In-111-DOTA-lanreotide and In-111-DOTA-Tyr3-octreotide versus F-18-FDG-PET for evaluation of somatostatin receptor-mediated radionuclide therapy. Ann Oncol 2001;12 suppl. 2:41–5.CrossRef
16.
Zurück zum Zitat Rodrigues M, Traub-Weidinger T, Li S, Ibi B, Virgolini I. Comparison of 111In-DOTA-DPhe1-Tyr3-octreotide and 111In-DOTA-lanreotide scintigraphy and dosimetry in patients with neuroendocrine tumours. Eur J Nucl Med 2006;33:532–40.CrossRef Rodrigues M, Traub-Weidinger T, Li S, Ibi B, Virgolini I. Comparison of 111In-DOTA-DPhe1-Tyr3-octreotide and 111In-DOTA-lanreotide scintigraphy and dosimetry in patients with neuroendocrine tumours. Eur J Nucl Med 2006;33:532–40.CrossRef
17.
Zurück zum Zitat Stridsberg M, Eriksson B, Oberg K, Janson ET. A comparison between three commercial kits for chromogranin A measurements. J Endocrin 2003;177:337–41.CrossRef Stridsberg M, Eriksson B, Oberg K, Janson ET. A comparison between three commercial kits for chromogranin A measurements. J Endocrin 2003;177:337–41.CrossRef
18.
Zurück zum Zitat Cimitan M, Buonadonna A, Cannizzaro R, Canzonieri V, Borsatti E, Ruffo R, et al. Somatostatin receptor scintigraphy versus chromogranin A assay in the management of patients with neuroendocrine tumors of different types: clinical role. Ann Oncol 2003;14:1135–41.PubMedCrossRef Cimitan M, Buonadonna A, Cannizzaro R, Canzonieri V, Borsatti E, Ruffo R, et al. Somatostatin receptor scintigraphy versus chromogranin A assay in the management of patients with neuroendocrine tumors of different types: clinical role. Ann Oncol 2003;14:1135–41.PubMedCrossRef
19.
Zurück zum Zitat Reubi JC, Kvols LK, Waser B. Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res 1990;50:5969–77.PubMed Reubi JC, Kvols LK, Waser B. Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res 1990;50:5969–77.PubMed
20.
Zurück zum Zitat Rodrigues M, Traub-Weidinger T, Leimer M, Li S, Andreae F, Angelberger P, et al. Value of 111In-DOTA-lanreotide and 111In-DOTA-DPhe1-Tyr3-octreotide in differentiated thyroid cancer: results of in vitro binding studies and in vivo comparison with 18F-FDG PET. Eur J Nucl Med Mol Imaging 2005;32:1144–51.PubMedCrossRef Rodrigues M, Traub-Weidinger T, Leimer M, Li S, Andreae F, Angelberger P, et al. Value of 111In-DOTA-lanreotide and 111In-DOTA-DPhe1-Tyr3-octreotide in differentiated thyroid cancer: results of in vitro binding studies and in vivo comparison with 18F-FDG PET. Eur J Nucl Med Mol Imaging 2005;32:1144–51.PubMedCrossRef
21.
Zurück zum Zitat Stivanello M, Berruti A, Torta M, Termine A, Tampellini M, Gorzegno G, et al. Circulating chromogranin A in the assessment of patients with neuroendocrine tumours. A single institution experience. Ann Oncol 2001;12:73–7.CrossRef Stivanello M, Berruti A, Torta M, Termine A, Tampellini M, Gorzegno G, et al. Circulating chromogranin A in the assessment of patients with neuroendocrine tumours. A single institution experience. Ann Oncol 2001;12:73–7.CrossRef
22.
Zurück zum Zitat Öberg K, Stridsberg M. Chromogranins as diagnostic and prognostic markers in neuroendocrine tumors. Adv Exp Med Biol 2000;482:329–37.PubMedCrossRef Öberg K, Stridsberg M. Chromogranins as diagnostic and prognostic markers in neuroendocrine tumors. Adv Exp Med Biol 2000;482:329–37.PubMedCrossRef
23.
Zurück zum Zitat Seregni E, Ferrari L, Bajetta E, Martinetti A, Bombardieri E. Clinical significance of blood chromogranin A measurement in neuroendocrine tumours. Ann Oncol 2001;12:69–72.CrossRef Seregni E, Ferrari L, Bajetta E, Martinetti A, Bombardieri E. Clinical significance of blood chromogranin A measurement in neuroendocrine tumours. Ann Oncol 2001;12:69–72.CrossRef
Metadaten
Titel
Concordance between results of somatostatin receptor scintigraphy with 111In-DOTA-DPhe1-Tyr3-octreotide and chromogranin A assay in patients with neuroendocrine tumours
verfasst von
Margarida Rodrigues
Michael Gabriel
Dirk Heute
Daniel Putzer
Andrea Griesmacher
Irene Virgolini
Publikationsdatum
01.10.2008
Verlag
Springer-Verlag
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 10/2008
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-008-0794-1

Weitere Artikel der Ausgabe 10/2008

European Journal of Nuclear Medicine and Molecular Imaging 10/2008 Zur Ausgabe